Phase 3 Juvenile Idiopathic Arthritis Clinical Trials
7 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–7 of 7 trials
Recruiting
Phase 3
Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents
Polyarticular Course Juvenile Idiopathic Arthritis
Alfasigma S.p.A.65 enrolled14 locationsNCT07554495
Recruiting
Phase 3
Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis
Polyarticular Course Juvenile Idiopathic Arthritis (JIA)
Duke University400 enrolled6 locationsNCT06654882
Recruiting
Phase 3
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
Juvenile Idiopathic Arthritis
AbbVie90 enrolled56 locationsNCT05609630
Recruiting
Phase 3
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis
Eli Lilly and Company190 enrolled80 locationsNCT03773965
Recruiting
Phase 3
OLE Study With Filgotinib in JIA
Juvenile Idiopathic Arthritis (JIA)
Alfasigma S.p.A.80 enrolled4 locationsNCT07553182
Recruiting
Phase 3
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
Systemic Juvenile Idiopathic Arthritis
Eli Lilly and Company58 enrolled55 locationsNCT04088396
Recruiting
Phase 3
The Efficacy of Intravenous Pulse in Attaining Remission in Refractory Juvenile Idiopathic Arthritis
Refractory Juvenile Idiopathic Arthritis (Despite 2 DMARDs Still Active)
Sohag University215 enrolled1 locationNCT06463379